Stay updated on Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content, indicating access is blocked. This change suggests that the requested record cannot be accessed at the moment, impacting the ability to view study details.
    Difference
    20%
    Check dated 2026-09-23T00:27:40.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision label on the page changed from v3.6.6 to v3.7.0, indicating an update to the page’s underlying system or content. This is a minor maintenance update rather than a change to the study information itself.
    Difference
    0.1%
    Check dated 2026-09-15T23:25:43.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Revision: v3.6.6 is now shown on the page, replacing the previous v3.6.5. This indicates a minor update to the page's revision metadata rather than a substantive change to the study content.
    Difference
    0.1%
    Check dated 2026-09-01T18:26:00.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page footer now shows Revision: v3.6.5 instead of v3.6.4, indicating a small system update; no clinical trial details or navigation changes are affected.
    Difference
    0.1%
    Check dated 2026-08-11T17:23:36.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.3 to v3.6.4, a maintenance update that does not change substantive content.
    Difference
    0.1%
    Check dated 2026-07-28T05:59:42.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    The page now lists Revision: v3.6.3 for the Study Protocol and Statistical Analysis Plan, replacing v3.6.2. This indicates the linked documentation has been updated to the latest version.
    Difference
    0.1%
    Check dated 2026-07-06T16:40:05.000Z thumbnail image

Stay in the know with updates to Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib, Fludarabine, Pembrolizumab in CLL Clinical Trial page.